drugset
drugset / Trial / NCT02454179

Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma

NCT02454179 ↗

Phase 2 Completed 78 enrolled Acerta Pharma BV Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Study of the combination of acalabrutinib (ACP-196) and pembrolizumab in subjects with advanced head and neck squamous cell carcinoma.

Timeline

Start
2015-05
Primary completion
2018-05
Completion
2018-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Acalabrutinib Small molecule — —
Subject Pembrolizumab Monoclonal antibody — —

Indications

head and neck squamous cell carcinoma